Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robotic vs. endoscopic: which biopsy method is more accurate for breast cancer?

NCT ID NCT07741734

Knowledge-focused Sponsor: Guangzhou Women and Children's Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study looks back at medical records of 150 women with breast cancer to compare two minimally invasive ways of checking whether cancer has spread to lymph nodes under the arm: robotic-assisted and endoscopic-assisted sentinel lymph node biopsy. The goal is to see which method finds the sentinel node more accurately, has fewer false negatives, and is safer in terms of complications, pain, arm function, and quality of life. It also tracks long-term outcomes like cancer recurrence and survival. The findings could help guide which technique is better for staging breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Robotic-assisted sentinel lymph node biopsy compared with endoscopic-assisted sentinel lymph node biopsy
What this could lead to
If robotic-assisted biopsy proves more accurate and safer, it could become a preferred minimally invasive option for staging breast cancer, potentially improving recovery and outcomes.
What could go wrong
This is a retrospective observational study, so it can only show associations, not prove cause and effect. Results may be influenced by patient selection and missing data, and the two techniques may turn out to be equally effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Oct 2021

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with breast cancer who underwent either robotic-assisted or endoscopic-assisted axillary lymph node dissection at the Department of Breast and Thyroid Surgery Center, Guangzhou Medical University Affiliated Women and Children's Medical Center.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18 to 80 years; * Patients with pathologically confirmed breast cancer; * Patients with cN0 or pre-neoadjuvant therapy cN1 breast cancer who are planned to undergo sentinel lymph node biopsy (SLNB); * Patients who provide written informed consent; * Eastern Cooperative Oncology Group performance status (ECOG PS): 0-1. Exclusion Criteria: * Clinical nodal stage greater than cN1 or inflammatory breast cancer; * Prior history of ipsilateral axillary or breast surgery; * Presence of distant metastasis (Stage IV); * Allergy to indocyanine green (ICG) or carbon nanoparticles; * Patients with other malignant tumors or severe comorbidities that render them unable to tolerate surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms

Contacts and locations

Locations

  • Guangzhou Women and Children's Medical Center, Guangzhou Medical University

    Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.